Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | TYR | P14679 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575442 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL8377843 | 0.91 | ALDH1A1 (0.68) | ALDH1A1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL930355 | 0.83 | KMT2A (0.58) | ALDH1A1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL14905034 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL23796073 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL2766815 | 0.80 | MEN1 (0.58) | ALDH1A1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL1632535 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL4882922 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL5028346 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MEN1PKMKMT2ANPSR1 | |
| SCHEMBL1072206 | 0.80 | ALDH1A1 (0.58) | ALDH1A1MEN1PKMKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649222-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2023-05-16 | — | — | US | disclosed |
| US-11649222-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2023-05-16 | — | — | US | disclosed |
| US-11649222-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2023-05-16 | — | — | US | disclosed |
| EP-3978488-A1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Universitetet I Oslo (NO) | 2022-04-06 | — | — | EP | disclosed |
| EP-3978488-A1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Universitetet I Oslo (NO) | 2022-04-06 | — | — | EP | disclosed |
| CN-109952297-B | Compound (I) | 奥斯陆大学 | 2022-02-25 | — | — | CN | disclosed |
| US-20210221791-A1 | COMPOUNDS | UNIVERSITETET I OSLO (NO) | 2021-07-22 | — | — | US | disclosed |
| EP-3497095-B1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | UNIV OSLO (NO) | 2021-07-14 | — | — | EP | disclosed |
| EP-3497095-B1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | UNIV OSLO (NO) | 2021-07-14 | — | — | EP | disclosed |
| US-10961223-B2 | Compounds | UNIVERSITETET I OSLO (NO) | 2021-03-30 | — | — | US | disclosed |
| WO-2018033719-A1 | COMPOUNDS | UNIVERSITETET I OSLO (NO) | 2018-02-22 | — | — | WO | disclosed |
| US-8778966-B2 | Quinolinone derivatives as PARP and tank inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-8466176-B2 | Fungicide hydroximoyl-tetrazole derivatives | BAYER CROPSCIENCE AG (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | VIALARD JORGE EDUARDO (BE) | 2013-01-17 | — | — | US | disclosed |
| US-8299256-B2 | Quinolinone derivatives as PARP and TANK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-30 | — | — | US | disclosed |
| EP-2134691-B1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-25 | — | — | EP | disclosed |
| US-20110105566-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2265118-A2 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | Bayer CropScience AG (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-01 | — | — | US | disclosed |
| WO-2009115557-A2 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105566-A1 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES | HAAO, CYP51A1, HPD | ALDH1A1 3321/4885MEN1 1827/4885PKM 1898/4885 |
| US-11649222-B2 | Compounds | SLC30A6, SLC39A11, SLC39A3 | ALDH1A1 3235/4885MEN1 2831/4885PKM 2850/4885 |
| US-10961223-B2 | Compounds | SLC30A6, SLC39A11, SLC30A5 | ALDH1A1 2991/4885MEN1 2663/4885PKM 2571/4885 |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | ALDH1A1 2041/4885MEN1 2135/4885PKM 905/4885 |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | ALDH1A1 2041/4885MEN1 2135/4885PKM 905/4885 |
| US-20210221791-A1 | COMPOUNDS | SLC30A6, SLC30A5, SLC39A11 | ALDH1A1 4328/4885MEN1 2394/4885PKM 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.